ABBV 951

Drug Profile

ABBV 951

Alternative Names: ABBV-951

Latest Information Update: 15 Feb 2017

Price : $50

At a glance

  • Originator AbbVie
  • Class Antiparkinsonians
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Parkinson's disease

Most Recent Events

  • 01 Feb 2017 Phase-I clinical trials in Parkinson's disease in USA (SC) (NCT03033498)
  • 25 Jan 2017 Preclinical trials in Parkinson's disease in USA prior to January 2017 (SC)
  • 25 Jan 2017 AbbVie plans a phase I trial for Parkinson's Disease in USA (NCT03033498) (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top